Skip to content

Randomized Study Of Novel Enuresis Alarm vs Standard Bedwetting Alarm

Randomized Study Of Novel Enuresis Alarm (GoGoband® )Vs Standard Nocturnal Enuresis Alarm (SNEA)

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05214131
Enrollment
16
Registered
2022-01-28
Start date
2022-04-29
Completion date
2025-06-13
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bedwetting, Nocturnal Enuresis, Urinary Incontinence

Keywords

bedwetting, biometric, artificial intelligence, machine learning, heart rate variability, nocturnal enuresis, enuresis, urinary incontinence

Brief summary

Identify the dry night rate in patients using the GoGoband® nocturnal enuresis device vs a standard Pflaundler bedwetting alarm.

Detailed description

3.1 Problem Statement At the present time, there are no side-by-side comparison studies of GoGoband® vs SNEA. Since many of the prior studies were conducted using variable outcome parameters that makes direct comparisons of studies difficult it would be beneficial to obtain comparable data from the 2 groups and compare dry night rates for the 2 devices. 3.2 Purpose of Study/Potential Impact Our preliminary quality improvement data indicates that the GoGoband® is more efficacious than both medication and SNEA in an uncontrolled environment when deidentified data was analyzed off our servers. Our present database does not allow us to discern if patients are monosymptomatic nocturnal enuresis (MNE) or non monosymptomatic nocturnal enuresis (NMNE). Without this ability as well as for controlling for behavioral and academic problems which are known to affect outcomes in nocturnal enuresis studies, the investigators are not able to compare our results definitively and accurately to other treatment modalities. Hypothesis Our hypothesis is that the GoGoband® is more effective than SNEA and Desmopressin in the treatment of Nocturnal Enuresis Primary Objective The primary objective of this study is to determine whether the GoGoband®\] is as effective or more effective in comparison to children who use SNEA in a population of MNE patients with no underlying Attention deficit hyperactivity disorder (ADHD) in a 3 month period. Secondary Objectives To ascertain if familial incidence of nocturnal enuresis has an effect on outcomes 5.1 General Design Description The investigators propose the following study in patients who have been evaluated for primary nocturnal enuresis in our Yale New Haven Clinics. * All patients to be evaluated for nocturnal enuresis will undergo standard evaluation and initial treatment for nocturnal enuresis which includes: * Assessment Of Bowel Habits, * Fill Out A Questionnaire To Evaluate For Voiding Dysfunction * Treatment with routine bedwetting protocol of: 1. Stopping drinks 1 HR before bedtime, meals at least 3 hrs before bedtime, eliminating milk and ice cream from dinner and on, making sure that bowel movements are occurring 4 times per week and treating appropriately if necessary. 2. On return visit bedwetters and parents will be given the option of using medication , no further treatment, or alarm therapy. 3. If patients choose alarm therapy, they will be asked if they wish to participate in the Randomized study comparing GoGoband® vs SNEA. 4. Alarms will be provided to the patients free of cost to participants 5. Patients in the alarm group will be treated for 3 months continuously. 6. Patients in the SNEA group will record nightly if they wet their clothes and the report will be recorded and reviewed weekly 7. GoGoband® patients' data will be automatically saved on the HIPPA Compliant servers and subsequently reviewed at the end of the week.

Interventions

DEVICEgogoband

use of biometric alarm to wake patient prior to wetting

DEVICESNEA group

standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred

Sponsors

Yale University
Lead SponsorOTHER
Southwest pediatric Device Consortium
CollaboratorUNKNOWN
Food and Drug Administration (FDA)
CollaboratorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 21 Years
Healthy volunteers
Yes

Inclusion criteria

1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 6 to 21 years 4. In good general health as evidenced by medical history and diagnosed with MNE 5. Ability to and be willing to adhere to the treatment regimen. -

Exclusion criteria

1. No patient may have had treatment of MNE in the past 6 months whether with medications or alarms 2. Current use of on ADHD medications, Tricyclics, SSRI's, NRI's or any antipsychotic medications. 3. Presence of Autistic Spectrum disorder, ADHD, genetic syndrome associated with developmental or learning disabilities 4. Treatment with another investigational drug or other intervention within last 6 months 5. Any form of Diabetes Mellitus or Diabetes Insipidus 6. No patient with known Chronic renal disease with moderate to severe renal impairment (defined as a creatinine clearance below 50mL/min). 7. No patient with known hyponatremia or a history of hyponatremia.

Design outcomes

Primary

MeasureTime frameDescription
Number of Wet Nights3 month periodComparison of alarms are to determine whether the GoGoband®\] is as effective or more effective in comparison to children who use SNEA in a population of MNE patients with no underlying ADHD. The number of wet nights in each group will be compared to each other providing a comparison of the data. The data will be compared using either a T test or Kruskal Wallis or anova depending on the number of comparisons performed and the data distribution is normal or not. If patient numbers are less than 10 per group no statistical analysis will be performed.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORIsrael Franco, MD

Dept of Urology, Yale School of Medicine

Participant flow

Recruitment details

patients with NE were asked to participate in a study without compensation to evaluate different bedwetting alarms

Pre-assignment details

patients were assigned randomly to gogoband group and standard alarm therapy

Baseline characteristics

Characteristic
Age, Continuous9.8 years
STANDARD_DEVIATION 2.6
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
13 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
12 Participants
Region of Enrollment
United States
16 participants
Sex: Female, Male
Female
5 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 80 / 3
other
Total, other adverse events
0 / 80 / 3
serious
Total, serious adverse events
0 / 80 / 3

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026